tbuckley/cabot-search huggingface dataset:
Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis.
Authors: F Violi, D Ferro, G Valesini, C Quintarelli, M Saliola, M A Grandilli, F Balsano
Journal: BMJ (1990)

To examine the relations among tissue plasminogen activator antigen, plasminogen activator inhibitor, the lupus anticoagulant, and anticardiolipin antibodies in patients with systemic lupus erythematosus.Prospective study of blood samples (a) from selected patients with systemic lupus erythematosus whose disease was and was not complicated by a history of thrombosis or recurrent abortions, or both, and (b) from a series of healthy controls with a similar age and sex distribution.University based medical clinic.23 Patients with definite systemic lupus erythematosus (American Rheumatism Association criteria), of whom 11 (eight women) aged 26-51 had a history of thrombosis or recurrent abortions, or both, and 12 (10 women) aged 23-53 had no such history. 15 Healthy subjects (10 women) aged 25-58 served as controls.Tissue plasminogen activator concentrations, plasminogen activator inhibitor activities, detection of the lupus anticoagulant, and values of anticardiolipin antibodies in the two groups of patients and in the patients with a history of thrombosis or abortions compared with controls. Other measurements included concentrations of proteins that are known to change during the acute phase of systemic lupus erythematosus--namely, fibrinogen, C3 and C4, and C reactive protein.Patients with a history of thrombosis or abortions, or both, had significantly higher values of tissue plasminogen activator and plasminogen activator inhibitor than patients with no such history. A significant correlation between tissue plasminogen activator and plasminogen activator inhibitor (r = 0.80) was found only in the patients with a history of complications of their disease. The lupus anticoagulant was detected in six of the 11 patients with a history of thrombosis or abortions when tested by measuring the activated partial thromboplastin time but was found in all 11 patients when tested by measuring the diluted activated partial thromboplastin time. Nine of these 11 patients had raised values of anticardiolipin antibodies. The findings showed no relation to the activity of the disease.A significant correlation between tissue plasminogen activator concentrations and plasminogen activator inhibitor activities was found only in patients whose systemic lupus erythematosus was complicated by a history of thrombosis or recurrent abortions. The findings show that these patients have raised plasminogen activator inhibitor activities, and the frequent association between these raised activities and the presence of the lupus anticoagulant suggests that the two may be linked.
Ultrasonic Decalcification of Calcified Cardiac Valves and Annuli
Authors: A. H. Brown, P. G. H. Davies
Journal: BMJ (1972)

Heavily calcified annuli increase the incidence of complications after prosthetic valve replacement-heart block, separation of the aorta or the atrium from the ventricle, late aneurysm formation, paravalvular leak, and haemolysis. An ultrasonic calculus-disintegrator has been developed to remove calcific deposits. The instrument is portable, robust, easily sterilized, inexpensive, and provides nebulized water at the ultrasonic tip which keeps the tissues cool, helps to break up the calculus by cavitation, and washes the calcific debris into the sucker. Preliminary trial on excised calcific valves showed the ultrasound instrument to be capable of removing most forms of calcification. In clinical prosthetic replacement of valves it enabled good clearance of the annulus to be performed in six out of seven cases, in one of which earlier operation had been unsuccessful because of calcification. Two elderly patients with pure calcific aortic stenosis were successfully treated by debridement of the aortic valve with ultrasound.
Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors
Authors: Philippe V. Afonso, Mourad Mekaouche, Franck Mortreux, Frédéric Toulza, Antoine Moriceau, Eric Wattel, Antoine Gessain, Charles R. M. Bangham, Guy Dubreuil, Yves Plumelle, Olivier Hermine, Jérome Estaquier, Renaud Mahieux
Journal: Blood (2010)
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial
Authors: Antoni Mas, Juan Rodés, Lourdes Sunyer, Luı́s Rodrigo, Ramon Planas, Victor Vargas, Lluı́s Castells, Dolores Rodrı́guez-Martı́nez, Conrado Fernández-Rodrı́guez, Ignasi Coll, Albert Pardo
Journal: Journal of Hepatology (2002)
TCT-143 Impact of manual thrombus aspiration on left ventricular remodeling: the echocardiographic substudy of the randomized Physiologic Assessment of Thrombus Aspiration in patients with ST-segment Elevation Myocardial Infarction (PATA STEMI) trial
Authors: Dejan Orlic, Milorad Tesic, Danijela Trifunovic, Bosiljka Vujisic, Branko Beleslin, Miodrag C. Ostojic
Journal: Journal of the American College of Cardiology (2014)
Canada Severely Limits Means for Conveying Tobacco Companies' Messages to Potential Users
Authors: Ken Sternberg
Journal: JAMA (1988)

IN A VICTORY that they say proves  tobacco lobby can be beaten, Canadian health and antismoking organizations have gained passage of one of the world's most stringent tobacco regulation laws.  The law—the Tobacco Products Control Act—bans all tobacco advertisements in newspapers and magazines published in Canada. (About 75% of magazines sold in Canada are published in the United States, and these are not affected by the ban.) The measure also prohibits tobacco companies from using their brand names in connection with sports or cultural events after a three-year phaseout period. In addition, cigarette makers will be required to include with each pack a list of the health hazards associated with tobacco and toxic chemicals produced by its smoke.  All point-of-sale advertising and promotions, such as signs at checkout counters or giving away cigarette lighters, also are banned. Fines of up to $300 000 (Canadian) will be levied against those
Frank Thomas Jenkinson
Authors: W E Sharman
Journal: BMJ (2004)

Former general practitioner Huddersfield (b Huddersfield 1925; q Leeds 1950), died on 12 June 2004 following a stroke.

After qualification and hospital posts Frank did his national service in the Royal Air Force before joining a practice in Huddersfield. Following retirement in 1990 he was dogged by serious ill health. He was a member of the BMA, Huddersfield Medical Society, and Woodsome Hall Golf Club. He leaves a wife, Margaret; four sons; and seven grandchildren.
LEFT CORONARY ARTERY ANGLE OF TAKEOFF IN PATIENTS WITH TRANSPOSITION OF THE GREAT ARTERIES AFTER ARTERIAL SWITCH OPERATION IS NOT RELATED TO FUNCTION BUT IS RELATED TO LEFT VENTRICULAR MASS: A CMR STUDY
Authors: Mark A. Fogel, Thomas Pawlowski, Marc Keller, Matthew Harris, Stephen Paridon, Kevin Whitehead
Journal: Journal of the American College of Cardiology (2013)
Vav1, but not Vav2, contributes to platelet aggregation by CRP and thrombin, but neither is required for regulation of phospholipase C
Authors: Andrew C. Pearce, Jonathan I. Wilde, Gina M. Doody, Denise Best, Osamu Inoue, Elena Vigorito, Victor L. J. Tybulewicz, Martin Turner, Steve P. Watson
Journal: Blood (2002)
Public service union mounts legal challenge to government's health white paper
Authors: C. White
Journal: BMJ (2010)

Unison, the UK’s largest public service union, is seeking a judicial review of the coalition government’s proposed healthcare reforms, on the grounds that the health secretary has failed to consult the public on the plans.

The move coincides with the launch of a national online petition by independent pressure group, the NHS Support Federation. The federation believes that the government’s proposals will result in the break-up of the NHS. It signals the start of a concerted union campaign to try to derail the plans.

Unison, which has 1.3 million members, contends that NHS chief executive David Nicholson’s instruction to all NHS chiefs to start implementing “immediately” the proposals outlined in the white paper Equity and Excellence: Liberating the NHS …
The Treatment of Drug Abuse: Programs, Problems, Prospects
Authors: Frank J. Ayd
Journal: JAMA (1972)

During the past decade, drug abuse spread like a contagious disease, ensnaring an alarming number of children, adolescents, and young and middle-aged adults. A concerned public knew that something had to be done to stop this epidemic and to treat its victims. An investigation carried out by the Joint Information Agency of the American Psychiatric Association and the National Institute of Mental Health resulted in this book. These agencies commissioned four experts on drug abuse to evaluate the various treatment programs available for drug misusers, and determine what a community can and should do to provide effective treatment for the drug abusers. The agencies, with Raymond Glasscote, Chief of the Joint Information Service, after much careful and astute preliminary surveying, selected for detailed analysis nine treatment programs, operating more than 40 facilities for persons who use drugs— mainly narcotics. From the visits and interviews, a wealth of important information emerged
Abstract 1859: CYLD downregulation induces aerobic glycolysis in human oral squamous cell carcinoma cells.
Authors: Takuya Nakamura, Satoru Shinriki, Mitsuhiro Hayashi
Journal: Cancer Research (2013)

Abstract Purpose: The hypermetabolic nature of cancer cells, especially their increased reliance on aerobic glycolysis which has been associated with more aggressive phenotype, is considered metabolic hallmarks of cancer cells including oral squamous cell carcinoma (OSCC) cells. However, its precise mechanisms remain unknown. Cylindromatosis (CYLD) is recognized as a tumor suppressor gene whereas little is available about its impact on cancer progression. Our unpublished data showed that lower CYLD expression was associated with poor prognosis in OSCC patients. The objective of our study was to address specific contributions of CYLD to the signature metabolic features of OSCC cells. Materials and methods: We determined the level of glucose consumption as well as lactate production to evaluate the effects of CYLD knockdown by siRNA on aerobic glycolysis in human OSCC cell lines. In addition, we measured extracellular acidification and oxygen consumption rates in OSCC cells by using XF Extracellular Flux Analyzers. Results: Downregulation of CYLD significantly suppressed cell proliferation through cell cycle arrest while it inhibited apoptosis induced by serum withdrawal in vitro. In addition, loss of CYLD led to the increase in both of glucose consumption and lactate production in several OSCC cell lines. Consistently, culture medium became more acidic by CYLD nockdown,compared with the control. Furthermore, glycolysis was promoted by CYLD downregulation whereas no significant difference was found in mitochondrial respiration. Conclusions: Dysfunction of CYLD may contribute to aerobic glycolysis without apparent influence on mitochondrial respiration. Further investigation on the advantage of such increased glycolysis and the change in metabolome profiling may lead to development of effective therapeutic strategies for OSCC and other malignancies. Citation Format: Takuya Nakamura, Satoru Shinriki, Mitsuhiro Hayashi. CYLD downregulation induces aerobic glycolysis in human oral squamous cell carcinoma cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1859. doi:10.1158/1538-7445.AM2013-1859
High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study
Authors: P Szulc, A Montella, P D Delmas
Journal: Annals of the Rheumatic Diseases (2007)

<h3>Objectives:</h3> The association of bone turnover markers (BTM) with bone loss and fracture risk in men is poorly studied. The morphological basis of such a relationship is unknown. The objective of this study was to evaluate the association between baseline BTM levels and subsequent bone loss and fracture risk in men. <h3>Methods:</h3> This study is a prospective 7.5-year follow-up of the cohort composed of 723 men aged 50–85 years. Serum concentrations of osteocalcin, bone alkaline phosphatase (BAP), procollagen type I N-terminal propeptide, C-terminal telopeptide of type I collagen (β-CTX-I) and urinary excretion of deoxypyridinoline and β-CTX-I were measured at baseline. Every 18 months, incident fractures were recorded and bone mineral density (BMD) was measured by dual energy <i>x</i> ray absorptiometry DXA (spine, hip, distal forearm, whole body). <h3>Results:</h3> Increase in BTM levels was associated with faster bone loss at the level of the trochanter, whole body and distal forearm. At the level of the distal radius and the ulna, increase in the serum BAP and β-CTX-I levels were associated with faster apparent, net and estimated endosteal bone mineral loss. BTM levels did not correlate with the periosteal expansion rate. BTMs were significantly associated with bone mineral loss but their predictive power was poor. BTMs did not predict incident fractures. <h3>Conclusions:</h3> In men aged 50 and over, accelerated bone turnover is associated with greater endosteal bone mineral loss. From a practical point of view, BTMs cannot be used for the prediction of accelerated bone loss or fractures in the clinical management of osteoporosis in men.
P5 Impact of national lung cancer awareness campaign on local referrals and outcomes in non-small cell lung cancer (NSCLC): Abstract P5. Table 1.
Authors: LD Calvert, S Chatterji
Journal: Thorax (2013)

<h3>Introduction</h3> Increased awareness of lung cancer symptoms, largely due to the national ‘Be Clear on Cancer’ campaign in 2012 targeting smokers with cough more than 3 weeks, contributed to 14% increased lung cancer detection rates in the UK. In NSCLC, early stage and performance status at presentation are crucial to prognosis, and the impact of these initiatives on radical treatment rates needs to be reviewed. We have therefore assessed possible impact of the campaign on local detection of radically-treatable NSCLC by reviewing presenting symptoms. <h3>Methods</h3> Patients diagnosed with NSCLC though our local thoracic oncology service in 2011 and 2012 (ie before and during the campaign) were reviewed. No other changes had been made to our diagnostic/treatment pathway between these 2 years. <h3>Results</h3> Between 2011 and 2012, number of patient diagnosed with NSCLC increased from 140 to 162. Patients presenting with stage 1–3a and good PS 0–2 increased from 33(23.5%) to 43(26.5%), largely due to increased stage 1 disease (table 1). In these patients, cough was a predominant symptom in 44% (2011) and 68% (2012). In 2011, 8(24%) patients presented to GP with unexplained cough as only symptom, with average symptom length 7.5months. In 2012, 18(42%) presented with unexplained cough, 14 through GP with average symptom length 3.3months, in 7 cases under 1month. <h3>Conclusions</h3> Our results mirror national increase in lung cancer diagnosed. We have seen an increased proportion of early stage disease, especially stage 1. Radical treatment rates increased by 6%, with curative surgery the main modality. Cough was a predominant symptom in patients presenting with radically-treatable NSCLC to their GP, and was the major focus of the national public awareness campaign in 2012. Locally, not only has the number of patients presenting with unexplained cough as a primary symptom increased between 2011 and 2012, but they are presenting sooner. It is possible therefore that the national campaign has contributed to detection of earlier stage disease in 2012 and translation to higher radical treatment rates. It will be interesting to see whether these initiatives have had similar effects on a national level and we await the LUCADA results for 2012.
Assessment of oral candidiasis in patients with respiratory disease and efficacy of a new nystatin formulation.
Authors: P J Thompson, H J Wingfield, R F Cosgrove, B O Hughes, M E Turner-Warwick
Journal: BMJ (1986)

Fifty consecutive patients with respiratory diseases who developed oropharyngeal candidiasis were assessed clinically and microbiologically before and after seven days9 treatment with nystatin suspension or pastilles (a new formulation). In 45 patients in whom microbiology yielded positive results there was frequent associated use of oral corticosteroids, antibiotics, sedatives, and inhaled corticosteroid, while in a few patients atropine analogues may have predisposed to infection. Dentures were worn by 32 of the infected patients. Concomitant treatment of dentures in chronically infected patients appeared to improve the therapeutic response. Pastilles and suspension were equally efficacious both clinically and microbiologically. The potential for enhanced drug delivery to the oropharynx suggests that nystatin pastilles may be useful in patients in whom poor compliance seems likely.
Defecation Syncope Caused by Pulmonary Embolism
Authors: Marin H. Kollef, David T. Schachter
Journal: Annals of Internal Medicine (1990)

Letters and Corrections1 July 1990Defecation Syncope Caused by Pulmonary EmbolismMarin H. Kollef, MD, David T. Schachter, MDMarin H. Kollef, MDSearch for more papers by this author, David T. Schachter, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-113-1-86_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: Defecation syncope accounts for approximately 5% of all patients who present with syncope (1-4). Pulmonary embolism presenting with syncope is reported in 17% of patients (5). Pulmonary embolism as a cause of defecation syncope has not been well described in the medical literature. We report the cases of four patients with this entity who presented to us over a 12-month period.A 60-year-old man had a brain tumor surgically removed. On the sixteenth postoperative day after the completion of defecation, he lost consciousness, fell from the commode, and died. Autopsy showed a saddle embolus to be the...References1. Wayne H. Syncope: physiological considerations and an analysis of clinical characteristics in 510 patients. Am J Med. 1961;30:418-38. CrossrefMedlineGoogle Scholar2. KapoorKarpfWieandPetersonLevey WMSJG. A prospective evaluation and follow-up of patients with syncope. N Engl J Med. 1983;309:197-204. CrossrefMedlineGoogle Scholar3. Pathy M. Defecation syncope. Age Ageing. 1978;7:233-6. CrossrefMedlineGoogle Scholar4. KapoorPetersonKarpf WJM. Defecation syncope: a symptom with multiple etiologies. Arch Intern Med. 1986;146:2377-9. CrossrefMedlineGoogle Scholar5. ThamesAlpertDalen MJJ. Syncope in patients with pulmonary embolism. JAMA. 1977;238:2509-11. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Marin H. Kollef, MD; David T. Schachter, MDAffiliations: Fitzsimons Army Medical Center Aurora, CO 80045-5001 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDefecation and Micturition may Cause Syncope in COVID-19 Patients on High Oxygen RequirementDefaecation syncope and pulmonary thromboembolism in a catPulmonary embolism presenting as syncope: Case report and review of the literatureInvoluntary defaecation in acutely injured patients: a useful clinical signSyncope in Older PersonsPulmonary Embolism Associated with Postoperative Deep BreathingAcute Pulmonary Embolism Triggered by the Act of Defecation 1 July 1990Volume 113, Issue 1Page: 86-86KeywordsAutopsyBrainConsciousnessDefecationPulmonary embolismSyncope ePublished: 1 December 2008 Issue Published: 1 July 1990 PDF downloadLoading ...
Is there a role for adjuvant therapy for resected non-small cell lung cancer?
Authors: J. R. Jett
Journal: Thorax (1999)

Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials PORT Meta-Analysis Trialists GroupBackground.The role of postoperative radiotherapy in treatment of patients with completely resected non-small-cell lung cancer (NSCLC) remains unclear.We undertook a systematic review and meta-analysis of the available evidence from randomised trials.Methods.Updated data were obtained on individual patients from all available randomised trials of postoperative radiotherapy versus surgery alone.Data on 2128 patients from nine randomised trials (published and unpublished) were analysed by intention to treat.There were 707 deaths among 1058 patients assigned postoperative radiotherapy and 661 among 1072 assigned surgery alone.Median follow-up was 3.9 years (2.3-9.8 for individual trials) for surviving patients.Findings.The results show a significant adverse effect of postoperative radiotherapy on survival (hazard ratio 1.21 [95% Cl 1.08-1.34]).This 21% relative increase in the risk of death is equivalent to an absolute detriment of 7% (3 11) at 2 years, reducing overall survival from 55% to 48%.Subgroup analyses suggest that this adverse effect was greatest for patients with stage I/II N0-N1 disease, whereas for those with stage III N2 disease there was no clear evidence of an adverse effect.Interpretation.Postoperative radiotherapy is detrimental to patients with early-stage completely resected NSCLC and should not be used routinely for such patients.The role of postoperative radiotherapy in the treatment of N2 tumours is not clear and may warrant further research (Lancet 1998;352: 257-63) * The results of meta-analyses do not always correlate with the results of very large (more than 1000 subjects) randomised prospective clinical trials.* Randomised prospective trials of adjuvant thoracic radiotherapy after complete resection of stages I-IIIA non-small cell lung cancer have not shown a survival advantage.* There is no proven role for adjuvant chemotherapy for patients with totally resected stages I-IIIA non-small cell lung cancer.* With surgery only the five year survival is 57% for patients with stage IB non-small cell lung cancer, 55%/39% for those with stage IIA/B disease, and 25% for those with stage IIIA disease.These poor survival rates justify further efforts to evaluate the efficacy of new adjuvant therapies.* No progress will be made in this difficult field without enrolling patients into randomised prospective trials.